Human Brevican Alexa Fluor™ Plus 680-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB40091AFP680
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Specificity
Clonality
Host
Isotype
Applications
Immunocytochemistry
Formulation, Preparation, and Storage
Formulation
Shipping
Stability & Storage
Background: Brevican
Ig‑like V-set domain, two link domains, a Glu-rich region, a central region with glycosaminoglycan (GAG) modifications, an EGF-like domain, a C-type lectin domain, and a C-terminal Sushi/CRP-like domain (2). Brevican is restricted to the CNS and is expressed by astrocytes, oligodendrocytes, and neurons (3‑7). A GPI-anchored alternate splice form exists that is truncated following the central (GAG) region (2, 8). Brevican is cleaved by multiple proteases and exists in a number of distinct fragments (5, 9, 10). Full-length brevican consists of a 97 kDa core protein with up to approximately 100 kDa of attached chondroitin sulfate but not heparan sulfate chains (4, 7, 11, 12). Brevican associates with the extracellular matrix, perineuronal nets, and astrocyte cell surfaces by means of its chondroitin sulfate, GPI anchor, hyaluronic acid-binding link domains, and the core protein (4, 7, 8, 13). The secreted isoform is dominant during brain development and is upregulated in astrocytes following brain injury (2, 14). In human and rat, an under-glycosylated form of brevican is upregulated in highly aggressive glioma but not in low-grade glioma or other brain pathologies (15, 16). In mouse and rat, levels of an ADAMTS4-generated 55 kDa N-terminal fragment increase during remodeling after excitotoxic injury (11, 12). Human brevican shares 90%, 80%, and 80% aa sequence identity with bovine, mouse, and rat brevican, respectively. Within the Ig‑like and two link domains, brevican shares 45%‑51% aa sequence identity with aggrecan, neurocan, and versican.
References
- Viapiano, M.S. and R.T. Matthews (2006) Trends Mol. Med. 12:488.
- Gary, S.C. et al. (2000) Gene 256:139.
- Jaworski, D.M. et al. (1994) J. Cell Biol. 125:495.
- Seidenbecher, C.I. et al. (1995) J. Biol. Chem. 270:27206.
- Hamel, M.G. et al. (2005) J. Neurochem. 93:1533.
- Ogawa, T. et al. (2001) J. Comp. Neurol. 432:285.
- Yamada, H. et al. (1997) J. Neurosci. 17:7784.
- Seidenbecher, C.I. et al. (2002) J. Neurochem. 83:738.
- Matthews, R.T. et al. (2000) J. Biol. Chem. 275:22695.
- Nakamura, H. et al. (2000) J. Biol. Chem. 275:38885.
- Mayer, J. et al. (2005) BMC Neurosci. 6:52.
- Yuan, W. et al. (2002) Neuroscience 114:1091.
- Deepa, S.S. et al. (2006) J. Biol. Chem. 281:17789.
- Jaworski, D.M. et al. (1999) Exp. Neurol. 157:327.
- Viapiano, M.S. et al. (2005) Cancer Res. 65:6726.
- Viapiano, M.S. et al. (2003) J. Biol. Chem. 278:33239.
Long Name
Alternate Names
Gene Symbol
Additional Brevican Products
Product Specific Notices
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.
For research use only